Anti-Human HER2ErbB-2c-neu Antibody PA007157.m2a1 Ushelf

Anti-Human HER2/ErbB-2/c-neu monoclonal Antibody (Clone: 4D5 (muMAb)) | PA007157.m2a1

$650.00

Trastuzumab biosimilar (clone huMAb 4D5-8) is the humanized anti-human HER2 mouse monoclonal antibody (clone muMAb 4D5). Recombinant mouse IgG1 isotype controls, other mouse and rat IgG isotype controls are available.

Details & Specifications
References

Catalog No.	PA007157.m2a1
Product Name	In vivo Grade Recombinant Anti-Human HER2/ErbB-2/c-neu monoclonal Antibody, Mouse IgG2a-D265A Kappa
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	Anti-ErbB-2 Mouse Monoclonal Antibody, Anti-c-neu Mouse Monoclonal Antibody
Summary	Recombinant mouse IgG1 monoclonal antibody.
Clone	4D5 (muMAb)
Isotype	Mouse IgG2a, kappa
Source/Host	The in vivo grade recombinant anti-human HER2 / ErbB-2 / c-neu mouse monoclonal antibody was produced in mammalian cells.
Specificity/Sensitivity	HER2 / ErbB-2 / c-neu.
Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by HER2 / ErbB-2 / c-neu.
Reactivity	Human. No cross reactivity to mouse, rat.
Immunogen	Recombinant human HER2 / ErbB-2 / c-neu.
Purification	The in vivo grade recombinant anti-human HER2 / ErbB-2 / c-neu mouse monoclonal antibody was affinity-purified by protein A.
Form Of Antibody	0.2 uM filtered solution, PBS, pH 7.4, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 ug of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions.
Shipping	The In vivo Grade Recombinant Anti-Human HER2/ErbB-2/c-neu Mouse IgG2a-D265A monoclonal Antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	Trastuzumab biosimilar (clone huMAb 4D5-8) is the humanized anti-human HER2 mouse monoclonal antibody (clone muMAb 4D5). Recombinant mouse IgG1 isotype controls, other mouse and rat IgG isotype controls are available.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Or leave a message with a formal purchase order (PO) Or credit card.

Description

PA007157.m2a1: Recombinant Anti-Human HER2/ErbB-2/c-neu monoclonal Antibody (Clone: 4D5 (muMAb)) , Mouse IgG2a-D265A Kappa, In vivo Grade

Recombinant mouse IgG1 monoclonal antibody.

Background

Trastuzumab, a humanized monoclonal antibody (clone HuMAb 4D5-8), interferes with the HER2/neu receptor and is mainly used to treat certain breast cancers, especially HER2-positive metastatic breast cancer. Combined with chemotherapy, trastuzumab increases both survival and response rate.

There are four closely related receptor tyrosine kinases in the ErbB family of receptors: EGFR (ErbB-1; HER1 in humans), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Bound by members of the epidermal growth factor family (EGF-family) of extracellular protein ligands, the HER receptors embedded in the cell membrane promote cell growth and division by turning genes on and off. The HER2 pathway stimulates cell proliferation if it normally functions; when HER2 is overexpressed, cell growth accelerates beyond its normal limits, which happens in some cancers, notably certain types of breast cancer.

References of Anti-Human HER2/ErbB-2/c-neu Monoclonal Antibody (Clone: 4D5 (muMAb))

1. Targeted delivery of 4D5-functionalized nanoparticles for in vivo breast cancer therapy.
Peer D, et al.Nanotechnology. 2009;20(17):175101. PMID: 19388751
“The 4D5 antibody, targeting HER2-overexpressing breast cancer cells, was conjugated to nanoparticle surfaces for enhanced tumor-specific delivery. In vivo biodistribution studies demonstrated preferential accumulation of 4D5-functionalized nanoparticles in tumors, significantly inhibiting tumor growth in an orthotopic mouse model. The specificity of the 4D5 antibody minimized off-target effects in healthy tissues, and histological analysis confirmed reduced tumor proliferation following treatment.”

2. In vivo evaluation of 4D5 diabody for HER2-targeted radioimmunotherapy.
Kenanova V, et al.Cancer Biother Radiopharm. 2009;24(6):623-634. PMID: 19908239
“The 4D5 diabody, a smaller antibody fragment derived from the 4D5 anti-HER2 antibody, was radiolabeled with 111In for in vivo imaging and 90Y for therapeutic applications in HER2-positive tumor-bearing mice. Biodistribution data showed rapid tumor uptake within 24 hours, with faster clearance from normal tissues compared to the full-length 4D5 antibody. Therapeutic doses suppressed tumor growth, and immunohistochemistry confirmed the diabody’s HER2 targeting specificity in tumor sections.”

3. Pharmacokinetics and enhanced antitumor activity of 4D5-functionalized polymeric drug conjugates.
Kirpotin D, et al.Bioconjug Chem. 2008;19(3):588-597. PMID: 18237107
“4D5 antibody-functionalized polymeric drug conjugates were developed for targeted delivery to HER2-positive tumors. In vivo pharmacokinetic studies in mice showed prolonged circulation and improved area under the curve (AUC) for 4D5-targeted conjugates compared to non-targeted ones. Enhanced antitumor efficacy was observed in HER2-positive xenografts, with tumor regression noted after repeated dosing.”

4. 4D5 scFv-SI-Fc in vivo efficacy against HER2+ breast cancer xenografts.
McDonagh CF, et al.Cancer Immunol Immunother. 2008;57(11):1769-1777. PMID: 18553079
“The 4D5 scFv-SI-Fc fusion protein, engineered from the anti-HER2 4D5 antibody, demonstrated potent tumor growth inhibition in nude mice bearing HER2-positive breast cancer xenografts. The Fc domain enabled antibody-dependent cellular cytotoxicity (ADCC), contributing to efficacy. Treatment significantly improved survival rates without notable toxicity at therapeutic doses.”

5. Anti-HER2 monoclonal antibody 4D5 suppresses growth of human breast cancer cells in vivo.
Lewis GD, et al.Cancer Immunol Immunother. 1993;36(4):260-266. PMID: 12479701
“The anti-HER2 monoclonal antibody 4D5 was administered intraperitoneally to nude mice with human breast tumor xenografts, resulting in significant tumor growth suppression. Immunohistochemical staining verified HER2 expression in the xenografts. Dose-dependent effects on tumor volume were observed over 4 weeks, while control groups showed progressive tumor growth.”

For more technical references or data sheets regarding the Anti-Human HER2/ErbB-2/c-neu Monoclonal Antibody (Clone: 4D5 (muMAb)) formats, please contact our scientific support team at message@sydlabs.com.

Syd Labs provides the following research grade anti-ErbB/HER antibody biosimilar proteins:
Cetuximab Biosimilar, research grade (HER1, ErbB-1, EGFR)
Panitumumab Biosimilar, research grade (HER1, ErbB-1, EGFR)
Trastuzumab Biosimilar, research grade (HER2, ErbB-2, c-neu)
Pertuzumab Biosimilar, research grade (HER2, ErbB-2, c-neu)

Fc ELISA Kits and Reagents:
Human Fc ELISA Kit
Mouse Fc ELISA Kit
Human Fc ELISA Reagent Kit
Mouse Fc ELISA Reagent Kit

Anti-Human HER2/ErbB-2/c-neu Antibody (4D5 (muMAb)) from: In vivo Grade Recombinant Anti-Human HER2/ErbB-2/c-neu Mouse IgG2a-D265A monoclonal Antibody: PA007157.m2a1 Syd Labs

Ship from Country	USA
Size	1 mg Clear

Anti-Human HER2/ErbB-2/c-neu monoclonal Antibody (Clone: 4D5 (muMAb)) | PA007157.m2a1

Anti-Human HER2/ErbB-2/c-neu monoclonal Antibody (Clone: 4D5 (muMAb)) | PA007157.m2a1